1 completed. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
Follow Primary Hyperoxaluria Type 3: new trials by email Literature Review of Primary Hyperoxaluria Type 3 trials Research Report on Primary Hyperoxaluria Type 3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients DCR-PHXC, Sterile Normal Saline (0.9% NaCl) - Primary Hyperoxaluria Type 3 | Phase 1 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 6 | 2020-09-14 | 2024-09-19 |
Carbohydrate Metabolism, Inborn Errors (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genetic Diseases, Inborn (1) · Hyperoxaluria (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Nutritional and Metabolic Diseases (1) · Urogenital Diseases (1) · Urologic Diseases (1)
nedosiran (1)
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1)
Germany (1) · Netherlands (1) · United Kingdom (1) · United States (1)